Original Article

Salivary anti-cyclic citrullinated peptide as a screening tool for rheumatoid arthritis

Volume 38 · Issue 1 Publish Date: March 31, 2023
Full Text PDF HTML
DOI
Nazanin Mortazavi ORCID
Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran image/svg+xml
Nafiseh Abdolahi ORCID
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran image/svg+xml
Mohsen Saeidi ORCID
Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran image/svg+xml
Mohammad Ali Vakili ORCID
Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran image/svg+xml
Pouria Mohebrad ORCID
Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran image/svg+xml
Nazanin Mortazavi, Nafiseh Abdolahi, Mohsen Saeidi, Mohammad Ali Vakili, & Pouria Mohebrad. (2023). Salivary anti-cyclic citrullinated peptide as a screening tool for rheumatoid arthritis. Archives of Rheumatology, 38(1), 095–100. https://doi.org/10.46497/ArchRheumatol.2023.9032
Full Text PDF HTML

Abstract

Objectives: This study aims to evaluate the sensitivity and specificity of salivary anti-cyclic citrullinated peptide 3 (anti-CCP3) for the early diagnosis of rheumatoid arthritis.

Patients and methods: Between June 2017 and April 2019, a total of 63 patients with rheumatoid arthritis (10 males, 53 females; mean age: 50.4±9.5 years; range, 27 to 74 years) and 49 healthy controls (8 males, 41 females; mean age: 49.3±9.3 years; range 27 to 67 years) were included. Salivary samples were collected by passive drooling. Anti-cyclic citrullinated peptide analyses of salivary and serum samples were performed.

Results: The mean polyclonal immunoglobulin (Ig)G-IgA anti-CCP3 salivary levels were significantly different in patients (149.2±134.2) compared to healthy controls (28.5±23.9). The mean polyclonal IgG-IgA anti-CCP3 serum levels were measured as 254.0±169.5 in patients and 3.8±3.6 in healthy individuals. The diagnostic accuracy analysis of salivary IgG-IgA anti-CCP3 results in an area under the curve (AUC) of 0.818, as well as 91.84% specificity and 61.90% sensitivity.

Conclusion: Salivary anti-CCP3 may be considered as an additional screening test for rheumatoid arthritis.

Similar Articles

Article Info
Published In
Journal Archives of Rheumatology
Volume / Issue Volume 38 · Issue 1
Pages 095-100
History
Published Online March 31, 2023
License
Affiliations
Nazanin Mortazavi ORCID
Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Nafiseh Abdolahi ORCID
Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Mohsen Saeidi ORCID
Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Mohammad Ali Vakili ORCID
Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Pouria Mohebrad ORCID
Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Cite this Article
Nazanin Mortazavi, Nafiseh Abdolahi, Mohsen Saeidi, Mohammad Ali Vakili, & Pouria Mohebrad. (2023). Salivary anti-cyclic citrullinated peptide as a screening tool for rheumatoid arthritis. Archives of Rheumatology, 38(1), 095–100. https://doi.org/10.46497/ArchRheumatol.2023.9032
Share
Outlines